Skip to main content
Top
Published in: Journal of Cardiovascular Translational Research 5/2020

Open Access 01-10-2020 | Arterial Diseases | Original Article

MGUS Predicts Worse Prognosis in Patients with Coronary Artery Disease

Authors: Zhao Xu, Yifeng Sun, Tianhong Xu, Yidan Shi, Lifan Liang, Peng Liu, Junbo Ge

Published in: Journal of Cardiovascular Translational Research | Issue 5/2020

Login to get access

Abstract

We performed a retrospective cohort study to analyze all 87 CAD patients with MGUS and 178 CAD patients without MGUS admitted in Zhongshan Hospital Fudan University from 2015 to 2017. Patients were followed up via regular patient visits or telephone, and the median follow-up period was 2.9 years. The end point of follow-up was the occurrence of major adverse cardiac events (MACE). CAD patients with MGUS had a higher risk of MACE than those without MGUS (log-rank P = 0.0015). After adjustment for other markers in the stepwise Cox regression model, MGUS was still related to the increasing risk of MACE incident (P = 0.002, HR = 2.308). Then, we constructed the nomogram based on the Cox regression model, and the concordance index (C-index) was 0.667. Hence, MGUS might be added into the risk model of CAD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Goldman, L., Schafer, A.I.. (2015). Goldman-Cecil medicine. 25th edition. Goldman, L., Schafer, A.I.. (2015). Goldman-Cecil medicine. 25th edition.
2.
go back to reference Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., et al. (2014). International myeloma working group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 15(12), e538–e548.CrossRef Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., et al. (2014). International myeloma working group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology, 15(12), e538–e548.CrossRef
3.
go back to reference Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. R. (2004). Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: The original Mayo Clinic series 25 years later. Mayo Clinic Proceedings, 79(7), 859–866.CrossRef Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., & Melton, L. R. (2004). Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: The original Mayo Clinic series 25 years later. Mayo Clinic Proceedings, 79(7), 859–866.CrossRef
4.
go back to reference Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., et al. (2002). A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England Journal of Medicine, 346(8), 564–569.CrossRef Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., et al. (2002). A long-term study of prognosis in monoclonal gammopathy of undetermined significance. The New England Journal of Medicine, 346(8), 564–569.CrossRef
5.
go back to reference Dimopoulos, M., Kyle, R., Fermand, J. P., Rajkumar, S. V., San, M. J., Chanan-Khan, A., et al. (2011). Consensus recommendations for standard investigative workup: Report of the international myeloma workshop consensus panel 3. BLOOD., 117(18), 4701–4705.CrossRef Dimopoulos, M., Kyle, R., Fermand, J. P., Rajkumar, S. V., San, M. J., Chanan-Khan, A., et al. (2011). Consensus recommendations for standard investigative workup: Report of the international myeloma workshop consensus panel 3. BLOOD., 117(18), 4701–4705.CrossRef
6.
go back to reference Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. R., Bradwell, A. R., Clark, R. J., et al. (2005). Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. BLOOD., 106(3), 812–817.CrossRef Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. R., Bradwell, A. R., Clark, R. J., et al. (2005). Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. BLOOD., 106(3), 812–817.CrossRef
7.
go back to reference Kumar, S., Dispenzieri, A., Katzmann, J. A., Larson, D. R., Colby, C. L., Lacy, M. Q., et al. (2010). Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features. BLOOD., 116(24), 5126–5129.CrossRef Kumar, S., Dispenzieri, A., Katzmann, J. A., Larson, D. R., Colby, C. L., Lacy, M. Q., et al. (2010). Serum immunoglobulin free light-chain measurement in primary amyloidosis: Prognostic value and correlations with clinical features. BLOOD., 116(24), 5126–5129.CrossRef
8.
go back to reference Dispenzieri, A., Lacy, M. Q., Katzmann, J. A., Rajkumar, S. V., Abraham, R. S., Hayman, S. R., et al. (2006). Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. BLOOD., 107(8), 3378–3383.CrossRef Dispenzieri, A., Lacy, M. Q., Katzmann, J. A., Rajkumar, S. V., Abraham, R. S., Hayman, S. R., et al. (2006). Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. BLOOD., 107(8), 3378–3383.CrossRef
9.
go back to reference Lachmann, H. J., Gallimore, R., Gillmore, J. D., Carr-Smith, H. D., Bradwell, A. R., Pepys, M. B., et al. (2003). Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 122(1), 78–84.CrossRef Lachmann, H. J., Gallimore, R., Gillmore, J. D., Carr-Smith, H. D., Bradwell, A. R., Pepys, M. B., et al. (2003). Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 122(1), 78–84.CrossRef
10.
go back to reference Shantsila, E., Wrigley, B., & Lip, G. Y. (2014). Free light chains in patients with acute heart failure secondary to atherosclerotic coronary artery disease. The American Journal of Cardiology, 114(8), 1243–1248.CrossRef Shantsila, E., Wrigley, B., & Lip, G. Y. (2014). Free light chains in patients with acute heart failure secondary to atherosclerotic coronary artery disease. The American Journal of Cardiology, 114(8), 1243–1248.CrossRef
11.
go back to reference Caimi, G., Hopps, E., Carlisi, M., Montana, M., Galla, E., Lo, P. R., et al. (2018). Hemorheological parameters in monoclonal gammopathy of undetermined significance (MGUS). Clinical Hemorheology and Microcirculation, 68(1), 51–59.CrossRef Caimi, G., Hopps, E., Carlisi, M., Montana, M., Galla, E., Lo, P. R., et al. (2018). Hemorheological parameters in monoclonal gammopathy of undetermined significance (MGUS). Clinical Hemorheology and Microcirculation, 68(1), 51–59.CrossRef
12.
go back to reference Lee, B. K., Durairaj, A., Mehra, A., Wenby, R. B., Meiselman, H. J., & Alexy, T. (2008). Hemorheological abnormalities in stable angina and acute coronary syndromes. Clinical Hemorheology and Microcirculation, 39, 43–51.CrossRef Lee, B. K., Durairaj, A., Mehra, A., Wenby, R. B., Meiselman, H. J., & Alexy, T. (2008). Hemorheological abnormalities in stable angina and acute coronary syndromes. Clinical Hemorheology and Microcirculation, 39, 43–51.CrossRef
13.
go back to reference Ercan, M., Konukoglu, D., & Erdem, Y. T. (2006). Association of plasma viscosity with cardiovascular risk factors in obesity: An old marker, a new insight. Clinical Hemorheology and Microcirculation, 35(4), 441–446.PubMed Ercan, M., Konukoglu, D., & Erdem, Y. T. (2006). Association of plasma viscosity with cardiovascular risk factors in obesity: An old marker, a new insight. Clinical Hemorheology and Microcirculation, 35(4), 441–446.PubMed
14.
go back to reference Cecchi, E., Mannini, L., & Abbate, R. (2009). Role of hyperviscosity in cardiovascular and microvascular diseases. Giornale Italiano di Nefrologia, 26(Suppl 46), 20–29.PubMed Cecchi, E., Mannini, L., & Abbate, R. (2009). Role of hyperviscosity in cardiovascular and microvascular diseases. Giornale Italiano di Nefrologia, 26(Suppl 46), 20–29.PubMed
15.
go back to reference Vincent, R. S. (2014). Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 89(10), 999–1009. Vincent, R. S. (2014). Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 89(10), 999–1009.
16.
go back to reference Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., et al. (2018). Long-term follow-up of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine, 378(3), 241–249.CrossRef Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., et al. (2018). Long-term follow-up of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine, 378(3), 241–249.CrossRef
17.
go back to reference Bibbins-Domingo, K., Gupta, R., Na, B., Wu, A. H., Schiller, N. B., & Whooley, M. A. (2007). N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA., 297(2), 169–176.CrossRef Bibbins-Domingo, K., Gupta, R., Na, B., Wu, A. H., Schiller, N. B., & Whooley, M. A. (2007). N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA., 297(2), 169–176.CrossRef
18.
go back to reference Schnabel, R., Rupprecht, H. J., Lackner, K. J., Lubos, E., Bickel, C., Meyer, J., et al. (2005). Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: Results from the AtheroGene study. European Heart Journal, 26(3), 241–249.CrossRef Schnabel, R., Rupprecht, H. J., Lackner, K. J., Lubos, E., Bickel, C., Meyer, J., et al. (2005). Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: Results from the AtheroGene study. European Heart Journal, 26(3), 241–249.CrossRef
19.
go back to reference Giannitsis, E., Spanuth, E., Horsch, A., Kleber, M. E., Koch, W., Grammer, T. B., et al. (2013). High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: Results from the Ludwigshafen risk and cardiovascular health (LURIC) study. Clinical Chemistry and Laboratory Medicine, 51(10), 2019–2028.CrossRef Giannitsis, E., Spanuth, E., Horsch, A., Kleber, M. E., Koch, W., Grammer, T. B., et al. (2013). High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: Results from the Ludwigshafen risk and cardiovascular health (LURIC) study. Clinical Chemistry and Laboratory Medicine, 51(10), 2019–2028.CrossRef
20.
go back to reference Biener, M., Giannitsis, E., Lamerz, J., Mueller-Hennessen, M., Vafaie, M., & Katus, H. A. (2016). Prognostic value of elevated high-sensitivity cardiac troponin T levels in a low risk outpatient population with cardiovascular disease. European Heart Journal Acute Cardiovascular Care, 5(6), 409–418.CrossRef Biener, M., Giannitsis, E., Lamerz, J., Mueller-Hennessen, M., Vafaie, M., & Katus, H. A. (2016). Prognostic value of elevated high-sensitivity cardiac troponin T levels in a low risk outpatient population with cardiovascular disease. European Heart Journal Acute Cardiovascular Care, 5(6), 409–418.CrossRef
21.
go back to reference Mayr, A., & Schmid, M. (2014). Boosting the concordance index for survival data—A unified framework to derive and evaluate biomarker combinations. PLoS One, 9(1), e84483.CrossRef Mayr, A., & Schmid, M. (2014). Boosting the concordance index for survival data—A unified framework to derive and evaluate biomarker combinations. PLoS One, 9(1), e84483.CrossRef
22.
go back to reference Lindholm, D., Lindback, J., Armstrong, P. W., Budaj, A., Cannon, C. P., Granger, C. B., et al. (2017). Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease. Journal of the American College of Cardiology, 70(7), 813–826.CrossRef Lindholm, D., Lindback, J., Armstrong, P. W., Budaj, A., Cannon, C. P., Granger, C. B., et al. (2017). Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease. Journal of the American College of Cardiology, 70(7), 813–826.CrossRef
23.
go back to reference Roffi, M., Patrono, C., Collet, J. P., Mueller, C., Valgimigli, M., Andreotti, F., et al. (2016). 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). European Heart Journal, 37(3), 267–315.CrossRef Roffi, M., Patrono, C., Collet, J. P., Mueller, C., Valgimigli, M., Andreotti, F., et al. (2016). 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). European Heart Journal, 37(3), 267–315.CrossRef
24.
go back to reference Pickering, J. W., Than, M. P., Cullen, L., Aldous, S., Ter Avest, E., Body, R., et al. (2017). Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection: A collaborative meta-analysis. Annals of Internal Medicine, 166(10), 715–724.CrossRef Pickering, J. W., Than, M. P., Cullen, L., Aldous, S., Ter Avest, E., Body, R., et al. (2017). Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection: A collaborative meta-analysis. Annals of Internal Medicine, 166(10), 715–724.CrossRef
25.
go back to reference Niccoli, G., Conte, M., Marchitti, S., Montone, R. A., Fracassi, F., Grippo, R., et al. (2016). NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. Cardiovascular Revascularization Medicine, 17(3), 162–168.CrossRef Niccoli, G., Conte, M., Marchitti, S., Montone, R. A., Fracassi, F., Grippo, R., et al. (2016). NT-proANP and NT-proBNP circulating levels as predictors of cardiovascular outcome following coronary stent implantation. Cardiovascular Revascularization Medicine, 17(3), 162–168.CrossRef
26.
go back to reference Zdravkovic, V., Mladenovic, V., Colic, M., Bankovic, D., Lazic, Z., Petrovic, M., et al. (2013). NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes. Kardiologia Polska, 71(5), 472–479.CrossRef Zdravkovic, V., Mladenovic, V., Colic, M., Bankovic, D., Lazic, Z., Petrovic, M., et al. (2013). NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes. Kardiologia Polska, 71(5), 472–479.CrossRef
27.
go back to reference Katzmann, J. A., Clark, R. J., Abraham, R. S., Bryant, S., Lymp, J. F., Bradwell, A. R., et al. (2002). Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48(9), 1437–1444.CrossRef Katzmann, J. A., Clark, R. J., Abraham, R. S., Bryant, S., Lymp, J. F., Bradwell, A. R., et al. (2002). Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48(9), 1437–1444.CrossRef
28.
go back to reference Shantsila, E., Wrigley, B., & Lip, G. Y. (2014). (2014) free light chains in patients with acute heart failure secondary to atherosclerotic coronary artery disease. The American Journal of Cardiology, 114(8), 1243–1248.CrossRef Shantsila, E., Wrigley, B., & Lip, G. Y. (2014). (2014) free light chains in patients with acute heart failure secondary to atherosclerotic coronary artery disease. The American Journal of Cardiology, 114(8), 1243–1248.CrossRef
29.
go back to reference Muller, J., Wallukat, G., Dandel, M., Bieda, H., Brandes, K., Spiegelsberger, S., et al. (2000). Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. CIRCULATION., 101(4), 385–391.CrossRef Muller, J., Wallukat, G., Dandel, M., Bieda, H., Brandes, K., Spiegelsberger, S., et al. (2000). Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. CIRCULATION., 101(4), 385–391.CrossRef
30.
go back to reference Uggla, B., & Nilsson, T. K. (2015). Whole blood viscosity in plasma cell dyscrasias. Clinical Biochemistry, 48(3), 122–124.CrossRef Uggla, B., & Nilsson, T. K. (2015). Whole blood viscosity in plasma cell dyscrasias. Clinical Biochemistry, 48(3), 122–124.CrossRef
31.
go back to reference Kwaan, H. C. (2013). Hyperviscosity in plasma cell dyscrasias. Clinical Hemorheology and Microcirculation, 55(1), 75–83.CrossRef Kwaan, H. C. (2013). Hyperviscosity in plasma cell dyscrasias. Clinical Hemorheology and Microcirculation, 55(1), 75–83.CrossRef
32.
go back to reference Malek, A. M., Alper, S. L., & Izumo, S. (1999). Hemodynamic shear stress and its role in atherosclerosis. JAMA., 282(21), 2035–2042.CrossRef Malek, A. M., Alper, S. L., & Izumo, S. (1999). Hemodynamic shear stress and its role in atherosclerosis. JAMA., 282(21), 2035–2042.CrossRef
33.
go back to reference Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., et al. (2006). Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine, 354(13), 1362–1369.CrossRef Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., et al. (2006). Prevalence of monoclonal gammopathy of undetermined significance. The New England Journal of Medicine, 354(13), 1362–1369.CrossRef
34.
go back to reference Dispenzieri, A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. R., Colby, C. L., et al. (2010). Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. LANCET., 375(9727), 1721–1728.CrossRef Dispenzieri, A., Katzmann, J. A., Kyle, R. A., Larson, D. R., Melton, L. R., Colby, C. L., et al. (2010). Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. LANCET., 375(9727), 1721–1728.CrossRef
35.
go back to reference Rajkumar, S. V. (2015). Risk of progression in MGUS. Lancet Haematol., 2(1), e6–e7.CrossRef Rajkumar, S. V. (2015). Risk of progression in MGUS. Lancet Haematol., 2(1), e6–e7.CrossRef
Metadata
Title
MGUS Predicts Worse Prognosis in Patients with Coronary Artery Disease
Authors
Zhao Xu
Yifeng Sun
Tianhong Xu
Yidan Shi
Lifan Liang
Peng Liu
Junbo Ge
Publication date
01-10-2020
Publisher
Springer US
Published in
Journal of Cardiovascular Translational Research / Issue 5/2020
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI
https://doi.org/10.1007/s12265-019-09950-w

Other articles of this Issue 5/2020

Journal of Cardiovascular Translational Research 5/2020 Go to the issue